title: Effect of low versus conventional dose cyclopenthiazide on platelet intracellular calcium in mild essential hypertension.
abstract: Platelet free intracellular calcium levels were measured during a double-blind, placebo-controlled parallel study to investigate the antihypertensive activity of 50 micrograms, 125 micrograms, and 500 micrograms cyclopenthiazide, in mild essential hypertension. Cytosolic free calcium levels were significantly higher in established hypertensive patients (135 +/- 28 nmol/l, P less than 0.001) but not in borderline hypertensive patients (123 +/- 26 nmol/l) compared with normotensive controls (111 +/- 9 nmol/l). A positive correlation between platelet free calcium level and systolic and diastolic blood pressure was confirmed (n = 68; r = 0.309 P = 0.01; r = 0.405 P less than 0.001, respectively). The 125-micrograms and 500-microgram doses of cyclopenthiazide produced mean decrements in blood pressure of 18/10 mmHg and 23/8 mmHg, respectively, (P less than 0.05 for both), after 8 weeks of therapy. The 50-microgram dose displayed no useful antihypertensive activity. Platelet free calcium levels fell by a similar amount in the four groups. The fall in blood pressure produced by the 125 and 500-microgram doses of cyclopenthiazide did not correlate with changes in platelet [Ca2+]i (r = 0.166 systolic and r = 0.169 diastolic). These findings do not support the hypothesis that changes in platelet cytosolic calcium levels are determined by the same factors that control blood pressure.
authors.affiliation: Department of Therapeutics and Pharmacology, Queen's University of Belfast, UK.
authors.forename: G E
authors.initials: GE
authors.lastname: McVeigh
authors.forename: S
authors.initials: S
authors.lastname: Copeland
authors.forename: J
authors.initials: J
authors.lastname: McKellar
authors.forename: D
authors.initials: D
authors.lastname: Johnston
mesh_terms: D001792:Blood Platelets / Q000378:metabolism*; D001794:Blood Pressure / Q000187:drug effects; D002118:Calcium / Q000097:blood*; D002986:Clinical Trials as Topic; D003518:Cyclopenthiazide / Q000008:administration & dosage* / Q000627:therapeutic use; D004232:Diuretics; D004311:Double-Blind Method; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage*
chemical_list: D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors; D002118:Calcium; D003518:Cyclopenthiazide